Search results for "Obesity"

JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide

JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide

JW Pharmaceutical announced on Aug. 18 that it has submitted an Investigational New Drug application to South Korea’s Ministry of Food and Drug...
Weight Unchanged but Waistband Tight? 5 Warning Signs of Rising Visceral Fat

Weight Unchanged but Waistband Tight? 5 Warning Signs of Rising Visceral Fat

If your overall weight remains stable but your stomach noticeably protrudes and your waistband feels tight, internal body fat may be quietly...
Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care

Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care

Hanmi Pharmaceutical has officially named its in-development obesity treatment "EPPE.
Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival

Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival

Olix announced on July 30 that its obesity drug candidate, "OLX501A," significantly outperformed a global rival...
Depressive Symptoms Linked to Higher Fatty Liver Risk in Young Adults

Depressive Symptoms Linked to Higher Fatty Liver Risk in Young Adults

Young adults in South Korea who experience depressive symptoms face roughly twice the risk of developing fatty liver...
Does Sugar Always Raise Cancer Risk? An Oncologist Explains What Really Matters

Does Sugar Always Raise Cancer Risk? An Oncologist Explains What Really Matters

Many people feel an immediate wave of guilt when faced with a sweet dessert. In particular, the widespread belief that...
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven

Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven

Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.
Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal

Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal

Samsung Biologics is making a major push into peptide-based medicines—widely used in weight-loss and diabetes...
Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market

Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market

The glucagon-like peptide-1 (GLP-1) obesity treatment market, long dominated by subcutaneous injections, is rapidly...
Maximizing Weight Loss vs. Protecting the Heart: The Paradox of Modern Anti-Obesity Drugs

Maximizing Weight Loss vs. Protecting the Heart: The Paradox of Modern Anti-Obesity Drugs

As global demand for anti-obesity medications surges, a fierce pharmaceutical race is underway to develop...